Literature DB >> 17008696

Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.

Javier Rangel1, Sima Torabian, Ladan Shaikh, Mehdi Nosrati, Frederick L Baehner, Chris Haqq, Stanley P L Leong, James R Miller, Richard W Sagebiel, Mohammed Kashani-Sabet.   

Abstract

PURPOSE: To assess the prognostic significance of nuclear receptor coactivator-3 (NCOA3) overexpression in primary cutaneous melanoma. PATIENTS AND METHODS: NCOA3 expression was assessed using immunohistochemical analysis of a melanoma tissue microarray (TMA) containing primary melanomas from 343 patients with defined histology and follow-up. The impact of the presence or absence of various prognostic factors on relapse-free survival (RFS) and disease-specific survival (DSS) of melanoma patients was assessed using Cox regression and Kaplan-Meier analysis. The impact of presence or absence of various factors on sentinel lymph node (SLN) metastasis was assessed using logistic regression analysis.
RESULTS: Increasing degree of NCOA3 expression was significantly predictive of SLN metastasis (P = .013) and the mean number of SLN metastases (P = .031). Kaplan-Meier analysis demonstrated a significant association between NCOA3 overexpression and reduced RFS (P = .021) and DSS (P = .030). Logistic regression analysis revealed increasing degree of NCOA3 expression to be an independent predictor of SLN status (P = .017). Multivariate Cox regression analysis showed the independent impact of NCOA3 expression on RFS (P = .0095) and DSS (P = .021). NCOA3 was the most powerful factor predicting DSS, outperforming tumor thickness and ulceration.
CONCLUSION: These results identify NCOA3 as a novel, independent marker of melanoma outcome, with a significant impact on SLN metastasis, RFS, and DSS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008696     DOI: 10.1200/JCO.2006.07.3833

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

1.  The function of FAK/CCDC80/E-cadherin pathway in the regulation of B16F10 cell migration.

Authors:  Guoshun Pei; Yan Lan; Weijie Lu; Lina Ji; Zi-Chun Hua
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

2.  miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.

Authors:  Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Mol Endocrinol       Date:  2015-06-12

3.  Melanoma prognostic model using tissue microarrays and genetic algorithms.

Authors:  Bonnie E Gould Rothberg; Aaron J Berger; Annette M Molinaro; Antonio Subtil; Michael O Krauthammer; Robert L Camp; William R Bradley; Stephan Ariyan; Harriet M Kluger; David L Rimm
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 4.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

Review 5.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

Review 6.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  A multimarker prognostic assay for primary cutaneous melanoma.

Authors:  Mohammed Kashani-Sabet; Suraj Venna; Mehdi Nosrati; Javier Rangel; Antje Sucker; Friederike Egberts; Frederick L Baehner; Jeff Simko; Stanley P L Leong; Chris Haqq; Axel Hauschild; Dirk Schadendorf; James R Miller; Richard W Sagebiel
Journal:  Clin Cancer Res       Date:  2009-11-03       Impact factor: 12.531

Review 8.  Melanoma biomarkers: current status and vision for the future.

Authors:  Allison R Larson; Eliz Konat; Rhoda M Alani
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23

Review 9.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

Review 10.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.